Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Current Liabilities Ratio 2 year CAGR for the year ending December 31, 2023: 16.25%

Akoya Biosciences Inc Current Liabilities Ratio 2 year CAGR is 16.25% for the year ending December 31, 2023, a 776.71% change year over year. The current liabilities ratio measures the proportion of a company's current liabilities in relation to its total assets. It is calculated by dividing current liabilities by total assets. This ratio indicates the percentage of a company's total assets that are financed by current liabilities, such as accounts payable and short-term debt. It helps assess the company's short-term solvency and its ability to meet immediate obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Akoya Biosciences Inc Current Liabilities Ratio for the year ending December 31, 2022 was 0.21, a 45.17% change year over year.
  • Akoya Biosciences Inc Current Liabilities Ratio for the year ending December 31, 2021 was 0.15, a -34.38% change year over year.
  • Akoya Biosciences Inc Current Liabilities Ratio for the year ending December 31, 2020 was 0.22, a -6.60% change year over year.
  • Akoya Biosciences Inc Current Liabilities Ratio for the year ending December 31, 2019 was 0.24.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email